Fujitsu seeks medical device partner to commercialize new diagnostic tool

In Tokyo last week, we met with Shozo Fujita, a biochemist working for electronics giant Fujitsu. Dr. Fujita and his colleagues work on several technologies at the intersection of biology and information technology. For example, the company has developed synthetic aptamers (biomolecules which bind t...

This research is archived and therefore no longer available. For further assistance please contact your Customer Success Manager or email ClientEngagementTeam@luxresearchinc.com. Thank you!

Related Research

Researchers significantly improve sequencing accuracy of Oxford Nanopore's technology

News Commentary | January 20, 2021

University of British Columbia researchers reported reducing sequencing errors using the portable MinION technology as well as PacBio's circular consensus sequencing from 10% to 0.005% through the application of a bar coding system. The application of unique molecular identifiers (UMIs) to ... Not part of subscription

Scientists develop a method to detect COVID-19 and its variants simultaneously

News Commentary | May 31, 2021

There are various methods to screen individuals for COVID‑19 today. However, these tests only tell you if you're "positive" or "negative" for COVID‑19. They do not give you details about which variants you may have if you test positive. That requires a further sequencing step to confirm, which may ... Not part of subscription

OriCiro Genomics raises ¥1 billion (~$9 million) Series B for DNA technology

News Commentary | July 29, 2021

The Japanese startup develops tools for the synthesis and amplification of DNA. The company claims improvements over the traditional PCR and E. coli cloning techniques through the use of an isothermal and cell‑free process. OriCiro plans to use the funds in order to expand its manufacturing ... Not part of subscription